p62, also called sequestosome 1 (SQSTM1), is a multifunctional signaling molecule that affects cell proliferation. Recently, we found accumulation of p62 in apocrine carcinoma of the breast, however, the biological role of p62 expression in apocrine carcinoma still remains unclear. To investigate whether p62 might contribute to tumor cell proliferation in apocrine carcinomas, we used the MDA-MB-453 (androgen receptor-positive, HER2-type) and MFM223 (androgen receptor-positive, triple-negative type) breast cancer cell lines as models of molecular apocrine carcinoma. Both MDA-MB-453 and MFM223 showed strong and d high p62 protein expression than MCF7 cells (androgen receptor-negative, luminal A type). Knockdown of p62 resulted in significant reduction of the cell proliferative activity in both MDA-MB-453 (P<0.01) and MFM223 (P<0.05). In conclusion, p62 could contribute to cell proliferation and represent a therapeutic target in apocrine carcinoma.
7002 Background: Survival rate should be used as the primary endpoint in clinical trials assessing the response of non-small-cell lung cancer to postoperative adjuvant chemotherapy. Single studies usually do not provide clear-cut conclusions because of limited sample size. We therefore performed a meta-analysis of all properly randomized clinical trials comparing long-term adjuvant chemotherapy with UFT, an oral fluorinated pyrimidine, to surgery alone in patients with completely resected non-small-cell lung cancer, and a number of subgroup analyses and tests for interaction were performed to evaluate generalizability of drug effect. Methods:Six such trials were identified. The analysis was based on individual patient data provided by the principal investigator of each trial. Data from 2,003 eligible patients were analyzed on an intention-to-treat basis. The endpoint of interest was overall survival at 5 years after surgery. Major prognostic factors were well balanced between the UFT group and surgery alone group. Results: The results of meta-analysis demonstrated that adjuvant chemotherapy with UFT significantly improved overall survival (5-year OS, HR, 0.77; 95%CI, 0.63–0.94; p=0.011, 7-year OS, HR, 0.74; 95%CI, 0.61–0.88; p=0.001). The 5-year OS rates and 7-year OS rates were 81.8%, 76.5% for the UFT arm and 77.2%, 69.5% for the surgery alone arm. Conclusions: We conclude that postoperative adjuvant chemotherapy with UFT has a beneficial effect uniformly in patients with completely resected early-stage non-small-cell lung cancer. No significant financial relationships to disclose.
